January 18, 2017 1:48 AM ET

Biotechnology

Company Overview of BioCardia, Inc.

Company Overview

BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. The company offers the Helix biotherapeutic delivery system product line that offers a catheter system for the local delivery of cells, gene, and protein therapeutics to the heart; and the Morph vascular access product line, which offers catheter products for interventional medicine. Its lead therapeutic candidate is the CardiAMP Cell Therapy System that is in Phase III pivotal trial for ischemic systolic heart failure. The CardiAMP Cell Therapy System comprises cell potency screening test, a point of care cell processing platform, and a biotherapeutic delivery system. BioCardi...

125 Shoreway Road

Suite B

San Carlos, CA 94070

United States

Founded in 2002

Phone:

650-226-0120

Fax:

650-631-3731

Key Executives for BioCardia, Inc.

Chief Executive Officer, President and Director
Age: 50
Total Annual Compensation: $253.8K
Principal Financial & Accounting Officer and Vice President of Finance
Age: 53
Total Annual Compensation: $203.8K
Vice President of Operations
Age: 50
Total Annual Compensation: $243.6K
Compensation as of Fiscal Year 2015.

BioCardia, Inc. Key Developments

Biocardia, Inc. Announces CardiAMP Pivotal Heart Failure Trial Initiated at Two US Centers

BioCardia, Inc. announced the initiation of the CardiAMP Heart Failure pivotal trial, a randomized, controlled, multi-center study of up to 260 patients evaluating CardiAMP cell therapy at up to 40 clinical sites in the United States. The trial has been initiated at two world-class centers: Johns Hopkins University, under the leadership of Dr. Peter Johnston and Dr. Gary Gerstenblith, and the University of Florida at Gainesville, under the leadership of Dr. David Anderson and Dr. Carl Pepine. The CardiAMP Therapy for heart failure integrates a biomarker panel, a cell processing system for autologous bone marrow-derived cells, and a unique transendocardial delivery system. This therapy will be reviewed under the PMA regulations by the FDA’s Center for Biologics Evaluation and Research (CBER) division.

BioCardia, Inc. Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017

BioCardia, Inc. Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 . Venue: Hilton San Francisco Union Square, 333 O'Farrell Street, San Francisco, CA 94102, United States. Speakers: Peter A. Altman, Chief Executive Officer, President and Director.

BioCardia DeviceCo, Inc. Approves Amended and Restated Certificate of Incorporation

BioCardia DeviceCo, Inc. announced that following the consummation of the merger, the company amended company's amended and restated certificate of incorporation to change name to BioCardia, Inc. The board of directors approved the amendment on October 24, 2016. The amendment to amended and restated certificate of incorporation is filed as Exhibit 3.1 hereto and became effective on October 26, 2016.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
September 30, 2016
--
Merger/Acquisition
August 23, 2016
Tiger X Medical, Inc.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact BioCardia, Inc., please visit www.biocardia.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.